Arvind N. Dasari, MD, MS, provides clinical insights on MRD testing modalities, highlighting factors that inform the decision on which platform to use in practice.
Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial
Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.
Leveraging Surgical Oncology Advances in Colorectal Cancer Care
Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.
Nivolumab/Ipilimumab Receive Type II Validation by EMA in MSI-H/dMMR mCRC
CheckMate-8HW assessed the efficacy of first-line nivolumab plus ipilimumab in patients with MSI-H/dMMR metastatic colorectal cancer.
Joleen Hubbard, MD, Highlights The “Exciting Space” Of Metastatic CRC
New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.
COVID-19 Pandemic Has Exacerbated CRC Surgery Disparities
Patients who are African American appeared to have worse clinical stages of colon and rectal cancer during surgery in 2020.
Adagrasib Combo Yields Encouraging Responses in KRAS G12C–Mutated CRC
Data from the phase 1/2 KRYSTAL-1 trial may support adagrasib plus cetuximab as a new standard in previously treated metastatic KRAS G12C–mutated CRC.